PSEN1 and Alzheimer disease: In summary, the present results suggest that the EB101 immunization protocols used in this study notably reduce the neuronal pathology associated with AD in APP/PS1 mouse models and offer a novel strategy of effective immunotherapy and prevention in human AD.